Searchable abstracts of presentations at key conferences in endocrinology

ea0037s3.2 | Non-classical causes of hypopituitarism (<emphasis role="italic">Endorsed by Endocrine Connections</emphasis>) | ECE2015

Genetic causes of hypopituitarism

Brue Thierry

Genetic causes of anterior pituitary hormone deficiencies may result in combined or isolated pituitary hormone deficiencies. These disorders represent a heterogeneous group of rare diseases leading to defective function of specific pituitary cell types. Since the first description of POU1F1 human mutations, several other genetic defects of transcription factors have been reported with variable degrees of phenotype-genotype correlations. However to date, despite the identificat...

ea0031s8.4 | Non functioning pituitary tumours (Supported by <emphasis role="italic">Endocrine-Related Cancer</emphasis> and the Pituitary Foundation) | SFEBES2013

Aggressive pituitary tumours and temozolomide treatment

Brue Thierry

Aggressive pituitary tumours are particularly challenging to clinicians in terms of diagnosis and treatment. They may first present as typical pituitary adenomas, with a delayed appearance of aggressive signs, or initially as aggressive tumours. Predicting pituitary tumour behaviour remains difficult: increased mitotic, Ki-67, and P53 indexes may be associated with tumour aggressiveness. True pituitary carcinomas are rare, representing about 0.2% of all pituitary tumours. The ...

ea0016s28.3 | GH: structure–function relationship | ECE2008

Multireceptor ligands in the treatment of pituitary adenomas

Brue Thierry

Using the currently available somatostatin receptor (sst) ligands octreotide and lanreotide, that are mainly sst2 agonists, about 60% of patients with acromegaly are adequately controlled. This prompted the development of new drugs targeting other sst subtypes or other receptors that are also expressed on adenomatous cells. BIM 23244 characterized by a high affinity for sst2 and sst5 had been found in vitro to allow a stronger inhibition of GH secretion than octreotide ...

ea0020s8.4 | Pituitary cell biology | ECE2009

Dual function of dopamine/somatostatin hybrid agonists

Saveanu Alexandru , Brue Thierry , Enjalber Alain , Jaquet Philippe , Barlier Anne

Somatostatin acts as an inhibitor of hormonal secretion and cell proliferation by acting through 5 somatostatin receptors subtypes (sst1–5). Coupling with Gi/o proteins is associated with effects on various transduction pathways, as adenylate cyclase inhibition or phosphatases activation. Dopamine receptor subtype 2 (D2DR) acts through coupling with similar G-proteins and transduction pathways. Sst, mostly sst2 and sst5, are coexpressed with D2DR in many neuroendocrine no...

ea0020p45 | Adrenal | ECE2009

Long-term follow-up of a 46XX patient with congenital lipoid adrenal hyperplasia due to a new mutation of the steroidogenic acute regulatory protein gene

Albarel Frederique , Simonin Gilbert , Morel Yves , Brue Thierry , Reynaud Rachel

Congenital lipoid adrenal hyperplasia (CLAH) is a severe disorder characterized by early impairment of both adrenal and gonadal steroidogenesis, leading to early adrenal failure and male sex reversal. The most common aetiology of CLAH is mutation of Steroidogenic acute regulatory protein (StAR) gene.Objective: We report evolution over 20 years of a 46XX patient harbouring a novel StAR gene mutation.Methods: Clinical, hormonal and i...

ea0063p410 | Adrenal and Neuroendocrine Tumours 2 | ECE2019

Large adrenal incidentalomas require a dedicated diagnostic procedure

Amodru Vincent , Taieb David , Guerin Carole , Paladino Nuncia Cinzia , Brue Thierry , Sebag Frederic , Castinetti Frederic

Introduction: The management of large non secreting adrenal tumors (at least 4 cm) is still a matter of debate as it is unclear whether imaging, especially 18F-FDG, can be used to characterize their potential malignancy. Moreover, the risk of new hypersecretion in non-operated tumors is uncertain. Our aim was to better characterize these large adrenal incidentalomas.Methods: Patients followed in our Center for a non-secreting large (at least 4 cm) adrena...

ea0035p675 | Growth hormone IGF axis basic | ECE2014

The etiologies of growth hormone insufficiences: about 170 cases

Fedala Soumeya , Haddam Ali El Mahdi , Chentli Farida , Zenati Akila , Brue Thierry , Amselem Serge , yaker Fetta

The GH deficiency (GHD) may be congenital with or without cause identified or acquired secondary to organic lesion in the hypothalamic region (HH). In all cases a magnetic resonance imaging is necessary.Aim: Investigate the causes of GHD Population and methodology GHD children were followed at the department of endocrinology. In addition to clinical examination, a testing hypophysiogramme is made with glucagon/propranolol/GH testing insulin on GH/cortiso...

ea0035p875 | Pituitary Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>) | ECE2014

Pre-surgical medical treatment, a major prognostic factor of remission in acromegaly

Albarel Frederique , Castinetti Frederic , Morange Isabelle , Conte-Devolx Bernard , Guibert Nicolas , Dufour Henry , Brue Thierry

Context: Following the recent evolution in therapeutic strategies for GH-secreting pituitary adenomas, determining optimal individualized patient management is now crucial.Objective: To determine whether pre-surgical medical treatment (PSMT) in patients with acromegaly improves surgical outcome and to specify thresholds for such a strategy.Methods and design: This retrospective study included 110 newly diagnosed acromegalic patient...

ea0022p13 | Adrenal | ECE2010

Pharmacokinetic evidence for hydrococortisone under and over replacement in adrenal insufficiency

Castinetti Frederic , Simon Nicolas , Ouliac Floriane , Lesavre Nathalie , Brue Thierry , Oliver Charles

Aim and methods: Cortisol substitution in adrenal insufficiency (AI) is a matter of debate. We performed a pharmacokinetic analysis of plasma and salivary cortisol following oral hydrocortisone intake in patients with AI, and a pharmacokinetic modelling simulation. Fifty patients with primary (n=20) or secondary (n=30) AI were recruited. After 24-h plasma and salivary cortisol measurements under usual hydrocortisone treatment, a pharmacokinetic modelling with dif...

ea0020p576 | Neuroendocrinology, Pituitary and Behaviour | ECE2009

Initial and long-term outcome of surgery in acromegaly: a ten-year, single centre study in 115 patients

Albarel Frederique , Castinetti Frederic , Morange Isabelle , Dubois Noemie , Dufour Henry , Conte-Devolx Bernard , Brue Thierry

Objective: To analyze characteristics of patients who had surgery for a GH-secreting adenoma in the past decade in our centre, to evaluate their initial outcome and long-term recurrence rate using stringent criteria and identify potential predictive factors of surgical remission.Methods: This retrospective study included 115 consecutive patients with acromegaly operated at the neurosurgical department of the Timone Hospital Marseille between 1997 and 200...